Press Releases Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Real-time Estimate Cboe BZX Other stock markets 12:35:01 2024-04-29 pm EDT			5-day change	1st Jan Change
25.24 ^USD	+72.25%		+72.87%	+56.26%

06:27pm	JonesTrading Downgrades Deciphera Pharmaceuticals to Hold From Buy, Adjusts Price Target to $25.60 From $16	MT
06:17pm	Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Shareholder Alert: Ademi LLP investigates whether Deciphera Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with ONO Pharmaceutical Co.	10:31am	PR
DCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Deciphera Pharmaceuticals, Inc. Is Fair to Shareholders	08:45am	BU
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion	07:01am	BU
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)	Apr. 18	PR
Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum	Apr. 09	BU
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	Feb. 27	BU
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results	Feb. 06	BU
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024	Feb. 01	BU
Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Feb. 01	BU
Deciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium	Jan. 18	BU
GENESIS Pharma announces an exclusive distribution agreement with Deciphera Pharmaceuticals to commercialize RIPRETINIB in 14 EU markets in Central and Eastern Europe	Jan. 10	AQ
Deciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product Company	Jan. 08	BU
Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18	Jan. 05	BU
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 02	BU
Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit	Nov. 29	BU
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	Nov. 07	BU
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT	23-10-31	AQ
Deciphera Pharmaceuticals Announces Third Quarter 2023 Financial Results	23-10-30	BU
Deciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCT	23-10-30	BU
EUCOPE Member Spotlight, Q&A with Deciphera	23-10-25	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Press Releases

Filters